Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsShares IssuedShares RepurchasedShort-Term Debt repayments
Ratios

Ani Pharmaceuticals (ANIP) Short-Term Debt repayments: 2020-2025

Historic Short-Term Debt repayments for Ani Pharmaceuticals (ANIP) over the last 4 years, with Sep 2025 value amounting to $2.0 million.

  • Ani Pharmaceuticals' Short-Term Debt repayments was N/A to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $297.1 million, marking a year-over-year change of. This contributed to the annual value of $292.5 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Short-Term Debt repayments of $2.0 million as of Q3 2025, which was down 0.00% from $2.0 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Short-Term Debt repayments high stood at $291.0 million for Q4 2024, and its period low was -$2.2 million during Q4 2022.
  • For the 3-year period, Ani Pharmaceuticals' Short-Term Debt repayments averaged around $42.3 million, with its median value being $2.0 million (2025).
  • Its Short-Term Debt repayments has fluctuated over the past 5 years, first tumbled by 101.17% in 2022, then surged by 13,033.33% in 2024.
  • Ani Pharmaceuticals' Short-Term Debt repayments (Quarterly) stood at $192.1 million in 2021, then tumbled by 101.17% to -$2.2 million in 2022, then remained steady at -$2.2 million in 2023, then skyrocketed by 13,033.33% to $291.0 million in 2024, then spiked by 170.80% to $2.0 million in 2025.
  • Its Short-Term Debt repayments stands at $2.0 million for Q3 2025, versus $2.0 million for Q2 2025 and $2.0 million for Q1 2025.